Carmot Therapeutics is catching up to companies with drugs designed to hit receptors that have become hot targets for metabolic diseases such as diabetes and obesity. But clinical-stage Carmot ...

LONDON — The booming obesity market is attracting another player, as pharma giant Roche said Monday it was acquiring Carmot Therapeutics and the company’s line of weight loss drug candidates ...

BERKELEY, Calif.--(BUSINESS WIRE)--Carmot Therapeutics, Inc., a clinical-stage biotechnology company applying its proprietary drug discovery platform, Chemotype Evolution, to discover and develop ...

CT-996 comes from the labs of Carmot Therapeutics, which Roche purchased last year. Carmot was pursuing the same metabolic targets as other companies, but it aimed to stand out with technology ...

BERKELEY, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics Inc. (Carmot), a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living ...

Obesity and diabetes-focused Carmot Therapeutics has unveiled plans to go public, braving icy IPO waters that have remained largely frozen over for biotech for more than a year. The 2023 Fierce 15 ...

Roche Holding AG agreed to pay as much as $3.1 billion for Carmot Therapeutics Inc., a developer of the new type of weight-loss treatments that’s sparked a pharma industry gold rush. The deal ...